BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29903888)

  • 1.
    Smeets MF; Tan SY; Xu JJ; Anande G; Unnikrishnan A; Chalk AM; Taylor SR; Pimanda JE; Wall M; Purton LE; Walkley CR
    Blood; 2018 Aug; 132(6):608-621. PubMed ID: 29903888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological
    Kon A; Yamazaki S; Nannya Y; Kataoka K; Ota Y; Nakagawa MM; Yoshida K; Shiozawa Y; Morita M; Yoshizato T; Sanada M; Nakayama M; Koseki H; Nakauchi H; Ogawa S
    Blood; 2018 Feb; 131(6):621-635. PubMed ID: 29146882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.
    Komeno Y; Huang YJ; Qiu J; Lin L; Xu Y; Zhou Y; Chen L; Monterroza DD; Li H; DeKelver RC; Yan M; Fu XD; Zhang DE
    Mol Cell Biol; 2015 Sep; 35(17):3071-82. PubMed ID: 26124281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
    Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
    Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
    Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
    Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms.
    Wang BA; Mehta HM; Penumutchu SR; Tolbert BS; Cheng C; Kimmel M; Haferlach T; Maciejewski JP; Corey SJ
    Leukemia; 2022 Oct; 36(10):2499-2508. PubMed ID: 35941213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
    Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
    Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
    Willekens C; Laplane L; Dagher T; Benlabiod C; Papadopoulos N; Lacout C; Rameau P; Catelain C; Alfaro A; Edmond V; Signolle N; Marchand V; Droin N; Hoogenboezem R; Schneider RK; Penson A; Abdel-Wahab O; Giraudier S; Pasquier F; Marty C; Plo I; Villeval JL; Constantinescu SN; Porteu F; Vainchenker W; Solary E
    Leukemia; 2023 Jun; 37(6):1287-1297. PubMed ID: 37100881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS.
    Huang YJ; Chen JY; Yan M; Davis AG; Miyauchi S; Chen L; Hao Y; Katz S; Bejar R; Abdel-Wahab O; Fu XD; Zhang DE
    Blood Adv; 2022 Dec; 6(23):6078-6092. PubMed ID: 36206200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
    Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
    Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
    Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
    Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
    Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
    Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
    Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
    PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.